Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.
| Autor: | Arance, Ana, de la Cruz-Merino, Luis, Petrella, Teresa M., Jamal, Rahima, Ny, Lars, Carneiro, Ana, Berrocal, Alfonso, Márquez-Rodas, Ivan, Spreafico, Anna, Atkinson, Victoria, Costa Svedman, Fernanda, Mant, Andrew, Khattak, Muhammad A., Mihalcioiu, Catalin, Jang, Sekwon, Cowey, C. Lance, Smith, Alan D., Hawk, Natalyn, Chen, Ke, Diede, Scott J. |
|---|---|
| Zdroj: | Journal of Clinical Oncology; Jan2023, Vol. 41 Issue 1, p75-85, 11p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|